Establishment Labs/$ESTA
Establishment Labs shares fall after its Q3 loss per share missed expectations amid higher US expansion and product-development spending, despite a revenue beat and raised full-year guidance.
7 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Establishment Labs
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
- Ticker
- $ESTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,004
- Headquarters
- Austin, United States
- Website
- www.establishmentlabs.com
ESTA Metrics
BasicAdvanced
$2.1B
-
-$1.29
1.09
-
Price and volume
Market cap
$2.1B
Beta
1.09
52-week high
$97.59
52-week low
$47.00
Average daily volume
416K
Financial strength
Current ratio
3.837
Quick ratio
2.274
Long term debt to equity
12.203
Total debt to equity
12.203
Interest coverage (TTM)
-0.68%
Profitability
EBITDA (TTM)
-8.984
Gross margin (TTM)
70.49%
Net profit margin (TTM)
-15.82%
Operating margin (TTM)
-7.63%
Effective tax rate (TTM)
18.08%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-3.44%
Return on equity (TTM)
-175.30%
Valuation
Price to revenue (TTM)
8.473
Price to book
96.15
Price to tangible book (TTM)
189.41
Price to free cash flow (TTM)
-50.122
Free cash flow yield (TTM)
-2.00%
Free cash flow per share (TTM)
-1.376
Growth
Revenue change (TTM)
38.55%
Earnings per share change (TTM)
-58.15%
3-year revenue growth (CAGR)
11.54%
3-year earnings per share growth (CAGR)
-19.28%
What the Analysts think about ESTA
Analyst ratings (Buy, Hold, Sell) for Establishment Labs stock.
Analyst projections of the future price of Establishment Labs stock.
Bulls say / Bears say
Third-quarter revenue rose 33.9%, with US sales up 119% as Motiva gained traction across more than 2,100 US accounts. This fast-growing market gives the company room to expand sales if surgeon use continues to deepen. (Establishment Labs)
The minimally invasive platform grew 124% in the third quarter, and FDA approval added 28 Motiva implant sizes for the US market. A broader range could help attract more patients and increase sales from the existing surgeon network. (Establishment Labs, Establishment Labs)
The company generated its first quarterly positive free cash flow and raised its 2026 revenue outlook to more than $274 million. Management also expects 25% revenue growth in 2027, suggesting growth may increasingly translate into stronger cash generation. (Establishment Labs)
Despite improving cash generation, the company remained loss-making, with a third-quarter GAAP net loss of $10.7 million. GAAP operating expenses rose to $52.3 million from $41.7 million a year earlier, so it still needs growth to outpace spending. (Establishment Labs)
International sales grew just 9.7% in the third quarter, well below US growth, and a higher-than-planned share of distributor sales weighed on gross margin. This mix could limit the benefit of strong headline revenue growth if it persists. (Establishment Labs)
Breast reconstruction remains a potential growth driver, but Motiva still needs FDA approval for that use and the review is ongoing. BTIG cut its revenue and adjusted EBITDA estimates after taking a more conservative view of the approval timeline, highlighting the risk of delayed contribution. (Establishment Labs, Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
ESTA Financial Performance
Revenues and expenses
ESTA Earnings Performance
Company profitability
Upcoming events
No upcoming events
ESTA News
AllArticlesVideos
Funds containing ESTA
Fund name | Fund size | $ESTA weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.16% |
iShares Ageing Population£AGES | $953M | 0.16% |
iShares Ageing Population€AGED | $903M | 0.16% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.